Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering DrugsHye Won Lee, Niklas Hammar, Matthew A. Cavender et al.|Journal of the American College of Cardiology|2018Cited by 465
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Dianna J. Magliano, Matthias Saathoff et al.|The Lancet Diabetes & Endocrinology|2020Cited by 93
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 DiabetesNeha J. Pagidipati, Jairo Cruz, Adam J. Nelson et al.|JAMA|2023Cited by 93
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology CommunityAdam J. Nelson, Christopher B. Granger, Neha J. Pagidipati et al.|Circulation|2021Cited by 79
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular DiseaseAdam J. Nelson, Christopher B. Granger, Lisa A. Kaltenbach et al.|JAMA Network Open|2022Cited by 73